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Abstract Three founder mutations in BRCA1 and BRCA2
contribute to the risk of hereditary breast and ovarian
cancer in Ashkenazi Jews (AJ). They are observed at
increased frequency in the AJ compared to other BRCA
mutations in Caucasian non-Jews (CNJ). Several authors
have proposed that elevated allele frequencies in the
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surrounding genomic regions reflect adaptive or balancing
selection. Such proposals predict long-range linkage dis-
equilibrium (LD) resulting from a selective sweep,
although genetic drift in a founder population may also act
to create long-distance LD. To date, few studies have used
the tools of statistical genomics to examine the likelihood
of long-range LD at a deleterious locus in a population that
faced a genetic bottleneck. We studied the genotypes of
hundreds of women from a large international consortium
of BRCA1 and BRCA2 mutation carriers and found that AJ
women exhibited long-range haplotypes compared to CNJ
women. More than 50% of the AJ chromosomes with the
BRCA1 185delAG mutation share an identical 2.1 Mb
haplotype and nearly 16% of AJ chromosomes carrying the
BRCA2 6174delT mutation share a 1.4 Mb haplotype.
Simulations based on the best inference of Ashkenazi
population demography indicate that long-range haplotypes
are expected in the context of a genome-wide survey. Our
results are consistent with the hypothesis that a local bot-
tleneck effect from population size constriction events
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could by chance have resulted in the large haplotype blocks
observed at high frequency in the BRCA1 and BRCA2
regions of Ashkenazi Jews.
Abbreviations
AJ Ashkenazi Jews
CIMBA Consortium of Investigators of Modifiers of
BRCA1 and BRCA2
CNJ Caucasian non-Jews
LD Linkage disequilibrium
MAF Minor allele frequency
MJ Median joining
PCA Principal components analysis
SNP Single nucleotide polymorphism
IBD Identity by descent
Introduction
Mutations in the BRCA1 and BRCA2 genes contribute to
risk of hereditary breast and ovarian cancers. Three founder
mutations in these two genes (BRCA1 185delAG, BRCA1
5382insC, and BRCA2 6174delT) are observed at a rela-
tively high frequency (*2% in total) in the general Ash-
kenazi Jewish population (Struewing et al. 1997; Tonin
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et al. 1996) compared with the occurrence of BRCA
mutations in the general population. In one study, 10.3% of
Ashkenazi women with invasive breast cancer, unselected
for family history, were carriers of one of the founder
mutations (King et al. 2003).
Recombination, genetic drift and natural selection all act
to shape the landscape of pairwise allelic associations, or
linkage disequilibrium, in a genomic region. Associations
will occur by chance in small populations due to random
changes in allele frequencies (Hartl and Clark 2007). When
a specific combination of alleles is beneficial for survival,
natural selection may increase the frequency of this hap-
lotype, thereby increasing levels of allelic association.
Applying the rationale of this model in reverse, if a region
is found to have exceptionally long-range haplotypes, then
this observation increases the likelihood that the region has
undergone recent positive selection (Sabeti et al. 2002;
Voight et al. 2006). There are several examples in literature
of this type of extended haplotype structure in regions
known to be influenced by natural selection. Deficiencies in
glucose-6-phosphate dehydrogenase (G6PD) levels cause
several blood disorders, but confer resistance to severe
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malaria. The G6PD A allele, defined by two nonsynony-
mous changes in the coding region of the G6PD gene, is
found on a conserved haplotype spanning more than
1.6 Mb (Saunders et al. 2005). Tishkoff et al. (Tishkoff
et al. 2007) identified three single nucleotide polymor-
phisms (SNPs) in the minichromosome maintenance 6
(MCM6) gene that are associated with the lactase persis-
tence phenotype. In that research, individuals homozygous
for the C-14010 allele exhibited a region of haplotype
homozygosity of average length 1.8 Mb, whereas individ-
uals homozygous for the G-14010 allele exhibited only a
1.8kb region of homozygosity (Tishkoff et al. 2007).
Although these studies provide examples of long haplo-
types consistent with positive selection, population genet-
ics theory and data from Drosophila melanogaster (which
also underwent an out-of-Africa bottleneck with humans)
show that bottlenecked demographics can also result in
focused regions of the genome having an apparently short
coalescence time. The latter strongly resemble long shared
haplotypes (Haddrill et al. 2005). Contrasting the merits of
natural selection versus neutral explanations for long hap-
lotypes must be done with caution, if the population is
known to have faced a demographic history with a
bottleneck. In capsule, that is the take-home message from
the work presented herein.
For more than 30 years, numerous authors have asser-
ted that the AJ diseases are a consequence of adaptive
evolution. In 2000, without doing a formal analysis, but on
the basis of estimates of the the time of common ancestry
of alleles of BRCA1 and BRCA2, Slatkin and Rannala
(Slatkin and Rannala 2000) concluded that these two
genes were likely to have been under selection in AJ. In
addition, BRCA1 was suggested to be a target of adaptive
evolution along the human and chimpanzee lineages on
the basis of now uncorroborated Hardy–Weinberg statis-
tics (Huttley et al. 2000). More recently, in a very con-
troversial review article, Cochran, Hardy and Harpending
(Cochran et al. 2006) made a series of arguments that
intelligence was being selected for through variation in the
homologous recombination pathway, specifically through
the function of BRCA1 and BRCA2 founder mutations.
Then, through the study of a recent small series of 85
Ashkenazi women, the BRCA1 185delAG and 5382insC
mutations were seen to occur on the two most common
haplotypes, found on 15 and 29% of chromosomes,
respectively (Pereira et al. 2007). We examined a *2 Mb
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region around BRCA1 or BRCA2 in hundreds of AJ
women to determine if the 185delAG, 5382insC and
6174delT founder mutations were carried on common
haplotypes and to attempt to disentangle the effects of
demography and natural selection in this genomic region.
Approximately, 16% of Ashkenazi chromosomes con-
taining the BRCA2-TCCGAAGA allele that is used here as
a surrogate for the 6174delT mutation share a long-range
haplotype extending more than 1.4 Mb and over half of
women with the 185delAG mutation core haplotype share
an identical haplotype extending over the entire 2.1 Mb
region examined. In contrast, chromosomes carrying
alternative core haplotypes showed much shorter haplo-
type sharing. The data gathered from the study of BRCA1
haplotypes are analogous: of the chromosomes sharing the
major 17-SNP BRCA1 haplotype in the CNJ women,
approximately 5.8% share a 1.27-Mb haplotype and only
3.3% share an identical 2.1-Mb haplotype. Multiple pro-
cesses including positive assortative mating (or endog-
amy), positive selection and a population bottleneck would
affect patterns of allelic association and lead to regions of
extended linkage disequilibrium. None of the predicted
departures from Hardy–Weinberg equilibrium allele fre-
quencies associated with non-random mating was
observed and therefore this hypothesis was dismissed.
Through simulation, we show that the observed extended
haplotypes can occur by genetic drift alone given that a
population bottleneck has occurred.
Materials and methods
Subjects and genotyping
Subjects included 372 Ashkenazi Jewish (AJ) women and
1,441 Caucasian, non-Jewish (CNJ) women sampled for a
BRCA2 modifier locus study(Gaudet et al. 2010) within
The Consortium of Investigators of Modifiers of BRCA1/2
(Chenevix-Trench et al. 2007). The AJ group consisted of
317 self-reported AJ women and 55 additional women with
the 6174delT founder mutation. These women were
included despite the fact that they did not indicate AJ
heritage, because this mutation is rarely observed outside
the AJ population (Struewing et al. 1999). In addition, a
principal components analysis (PCA) demonstrates that
these 55 women cluster with women self-reported as AJ
(data not shown). All women had deleterious mutations in
BRCA2 and were genotyped on the Affymetrix Genome-
Wide Human SNP Array 6.0 platform. SNPs and individ-
uals were filtered based on the method recently discussed
in detail (Gaudet et al. 2010). We extracted a *2.1-Mb
region surrounding BRCA2 consisting of 1,402 SNPs to
investigate LD patterns and haplotype structure.
Subjects from the Consortium of Investigators of Mod-
ifiers of BRCA1 and BRCA2 (CIMBA) harboring delete-
rious BRCA1 mutations (Antoniou et al. 2010) included
316 and 297 women with the AJ founder 185delAG and
5382insC mutations, respectively, and 2,186 women with
other mutations (designated CNJ for future reference).
DNA samples from these women were genotyped on the
Illumina Infinium 610 K array platform. For more infor-
mation on the study subjects and genotyping (including
quality control) see Antoniou et al. (2010).
Linkage disequilibrium and core haplotype
Linkage disequilibrium (LD) among pairs of markers and
LD block boundaries were estimated from genotype data
using the program Haploview (Barrett et al. 2005). The
program’s default parameters were used except that the
minor allele frequency cutoff was set to 0.05.
The core BRCA2 haplotype, at which we looked for
extended homozygosity, is an LD block consisting of 8
SNPs: rs543304, rs206081, rs4942448, rs11571700,
rs11571725, rs4942485, rs206146 and rs15869. The block
spans approximately 60 kb within the gene.
The core 17-SNP BRCA1 haplotypes for AJ and the CNJ
women spansapproximately 274 and257 kb, respectively, and
consists of the following SNPs: rs382571 (only in AJ core),
rs9911630, rs11657053, rs8176273, rs8176265, rs1799966,
rs3737559 (only in CNJ core), rs1060915, rs16942, rs799917,
rs16940, rs799923, rs9646417, rs11651341, rs4534897,
rs4793234, rs11657004 and rs9912203.
Haplotype estimation
Haplotypes for all subjects were estimated using SNPHAP
(Clayton, http://www-gene.cimr.cam.ac.uk/clayton/software).
SNP positions and chromosomes that could not be unam-
biguously phased were excluded from analysis.
Extended haplotype structure
Markers that were uninformative for LD analysis
(MAF\0.05) were removed from the estimated haplotypes.
To determine a consensus haplotype and the extent of
haplotype structure, we walked SNP by SNP to the left and
right of the core haplotype independently. Chromosomes
carrying the consensus haplotype were carried forward and
the rest were filtered out. SNPs that filtered more than 20%
of the remaining chromosomes were considered ‘‘wobble’’
positions and any allele was permitted at these sites. We
determined the left- and right-hand border of the extended
haplotype as either (1) the position before a 10-SNP win-
dow consisting of five or more wobble positions or (2) the
position where less than 20% of the chromosomes share the
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extended haplotype, whichever was closest to the core
haplotype. We performed this analysis for the chromo-
somes carrying the BRCA2-TCCGAGGA and those car-
rying other alleles separately. The same was done for the
BRCA1 cohort data; chromosomes from individuals with
the 185delAG mutation carrying the BRCA1-GGAGAG
GGAGGAGGGGA were analyzed separately from those
carrying a different haplotype. We also examined the
extended haplotype homozygosity, a measure designed to
quantify the decay of association between a core haplotype
and other alleles, with the program Sweep (Sabeti et al.
2002).
Simulations
The program msHOT (Hellenthal and Stephens 2007) was
used to generate population samples based on both the
one-bottleneck and two-bottleneck models of Slatkin
(Slatkin 2004). msHOT can take a specific recombination
landscape. We specified the local recombination rates (in
cM/Mb) for the 2.1 Mb region surrounding BRCA2 fol-
lowing the estimates of Myers et al. (Myers et al. 2005).
The msHOT code for the single bottleneck model can be
found in Appendix A. The size of the largest haplotype
block from each sample was retained if it exceeded
715 kb, and from the counts of these mutation-drift
recombination samples, we obtained the chance of
recovering large haplotype blocks by drift in this demo-
graphic scenario.
Core haplotype figures
These were generated using the hplot2 perl script written
by Xiaoquan Wen and generously provided by him and
Sridhar Kudaravalli from the University of Chicago.
Population differentiation metrics
F-statistics and Hardy–Weinberg measures were calculated
using the tools developed by Stefanov et al. (Stefanov et al.
2008).
Principal components analysis (PCA)
Principal components analysis was performed using the
smartpca program within the EIGENSOFT suite (Price
et al. 2006).
Haplotype network diagrams
These were drawn using the median joining (MJ) algorithm
as implemented in Network 4.5.1.6., released 31 December
2009 from Fluxus-Engineering.
Tajima’s D calculation
This was performed using the R-script kindly supplied by
Christopher Carlson for his publication on genome-wide
characterization (Carlson et al. 2005).
Results
We examined a region of approximately 2 Mb surrounding
BRCA1 or BRCA2 to explore the linkage disequilibrium
(LD) patterns and haplotype structure and to determine
whether these regions exhibit signatures of natural selec-
tion. Genotype data for two separate cohorts of women
carrying deleterious BRCA1 or BRCA2 mutations were
used to estimate pairwise LD. The BRCA2 cohort included
372 Ashkenazi Jewish (AJ) women consisting of 317 self-
reported Ashkenazi and 55 women who self-reported as
Caucasian non-Jews, but carried the AJ founder 6174delT
mutation. The BRCA1 cohort included 316 and 297 women
with AJ founder 185delAG and 5382insC mutations,
respectively. The BRCA2 gene is located in a region of
high LD, and the major haplotype for the LD block span-
ning 60 kb of the gene (TCCGAAGA) is found on 55% of
chromosomes. We hypothesized that this was a surrogate
for the 6174delT mutation, and therefore used it as the core
for determining the extent of haplotype structure in the
region (Fig. 1). SNPHAP, an Expectation Maximization
algorithm haplotype estimation program, was used to
generate haplotypes from the genotype data of all 1,402
SNPs from this genomic region. Uninformative markers
were removed from the haplotypes, and the remaining 545
SNPs were analyzed. A total of 412 chromosomes repre-
senting 328 women carried the BRCA2-TCCGAAGA
haplotype including 8 of the 13 women who did not indi-
cate that they were of Ashkenazi descent. We separately
examined the extended haplotype structure for chromo-
somes with the BRCA2-TCCGAAGA allele and for those
chromosomes with other alleles. A total of 18% of the 412
chromosomes carrying the BRCA2-TCCGAAGA allele
shared a haplotype extending more than 1.4 Mb, while
chromosomes with other alleles shared a haplotype
approximately half that length (715 kb) (Fig. 2a). A similar
pattern was observed when examining women with the
BRCA1 185delAG mutation. Approximately, half of the
chromosomes carried the major 20-SNP haplotype
(GGAGAGGGGAGGAAGGGGAG) for the LD block
extending across the gene (Supplementary Fig. 1) and, of
those, 51.9% shared an identical 2.1-Mb haplotype sur-
rounding BRCA1.
To assess the significance of this extended haplotype, we
need to evaluate how unlikely it is to have such a large
haplotype given the other haplotypes in the region and the
Hum Genet (2011) 130:685–699 691
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demographic history of Ashkenazim. The general strategy
was to produce simulated data sets from a population
whose history of bottlenecks and growth matched the his-
torical record of Ashkenazim, and to use these simulations
to determine how often haplotypes as long as those
observed occur by purely neutral processes. We performed
coalescent-based simulations using the popular simulation
program msHOT (Hellenthal and Stephens 2007; Hudson
2002) and a set of demographic parameters matching the
founding population size and expansion derived from other
genetic data (Slatkin 2004). We considered a 2-Mb win-
dow, with a recombination landscape for the BRCA2 region
of chromosome 13 based on the Myers et al. (Myers et al.
2005) genetic map of humans. It required 1250 realizations
of the simulation to produce a common haplotype block of
715 kb (equal to the length of the haplotype observed on
AJ chromosomes without the 6174delT surrogate allele),
suggesting that the observation of a haplotype block of this
size may be unlikely. However, the correct question is not
whether a long haplotype in this particular region will be
found by chance; it is rather to ask whether a 1.4-Mb
haplotype will be found among some subset of individuals
given that others share a 715-kb haplotype. The existence
of the 715-kb haplotype indicates that this is a region of the
genome that has fairly shallow common ancestry (a recent
coalescence time). Given that the region has a recent
coalescence, we then ask whether there might also be even
longer haplotypes in the sample. The simulations show that
conditional on the sample having a 715-kb haplotype
block, it is not at all unlikely that a 1.4-Mb haplotype block
is present, associated with the alternative allele and shared
by more than 18% of the chromosomes. In addition, at least
5% of chromosomes share a common haplotype across the
2.1-Mb region in more than 30% of simulated data sets. In
summary, long-range haplotype structure is not unlikely to
occur by purely neutral processes in this region of the
genome, given what we know about the demography of the
population and the structure of the genetic variation in this
region of the genome, suggesting that the Ashkenazi bot-
tleneck drove this region to have a recent coalescence.
We next performed the same analysis on 1,441 Cauca-
sian, non-Jewish (CNJ) women from the BRCA2 cohort
and 2,186 CNJ women from the BRCA1 cohort. We found
no evidence of an extended haplotype in CNJ samples
across either BRCA2 or BRCA1. A haplotype nearly five
times shorter (*326 kb) than that observed in the Ash-
kenazi women is observed in 10% of chromosomes car-
rying the BRCA2-TCCGAAGA allele and a 60-kb
haplotype is observed in 18% of chromosomes carrying
other core haplotypes (Fig. 2b). Of the chromosomes
sharing the major 20-SNP BRCA1 haplotype (AACAGA-
GAAGAGAGAAAAGG) in the CNJ women, approxi-
mately 5.8% share a 1.27-Mb haplotype and only 3.3%
share an identical 2.1-Mb haplotype. While this suggests
that some extended haplotype structure exists in CNJ
individuals in these two regions, it is to a much lesser
extent than that observed in AJ individuals.
There are multiple explanations for the discrepancy
between Ashkenazi and CNJ haplotype structure. The core
haplotype, which is seen on more than half of the chro-
mosomes studied, may be a surrogate for the 6174delT
mutation. This mutation is estimated to have arisen only 29
generations ago (Neuhausen et al. 1998), and hence, there
is a higher likelihood for the persistence of the haplotype,
resulting in the observed haplotype homozygosity. In light
of the recombination landscape, which includes several
hotspots (Supplementary Fig. 1), this is unlikely to be the
cause of the observed haplotype structure. Alternatively,
a
b
Fig. 1 Linkage disequilibrium across a 570-kb region in 372
Ashkenazi women. a Haploview output showing LD blocks across
region. Black block represents the core haplotype. b Haplotypes
estimated using SNPHAP for each of the LD blocks. Haplotypes
observed in at least 1% of chromosomes are shown in order of
frequency (most frequent first)
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the haplotype structure observed might be a result of
endogamy in the Ashkenazi population (i.e., marrying
within one’s own ethnic group, social class, etc.). This
selective mating practice would cause a loss of genetic
variation and an increase in the extent of LD (Gibson et al.
2006). Under endogamy, one would expect that Ashkenazi
individuals will exhibit positive values of the inbreeding
coefficient FIS (Weir and Cockerham 1984), reflecting
a heterozygote deficiency relative to Hardy–Weinberg
equilibrium expectations. Contrary to what would be
expected under endogamy and inbreeding, a large propor-
tion of SNPs in the region encompassing BRCA2 have
Fig. 2 Extended haplotype structure observed in (a) 372 Ashkenazi
women across a 2.1-Mb region and (b) 1441 Caucasian, non-Jewish
women across an 805-kb region. Each row represents an individual.
Tick marks show SNP locations, red triangles mark the boundaries of
the 8-SNP core BRCA2 haplotype, and blue triangles mark the
boundaries of the (a) 1.4 Mb extended haplotype and (b) 715 kb
extended haplotype in the AJ and CNJ, respectively. Long horizontal
red lines represent the core haplotype, while interruptions in that
haplotype observed in the data by the presence of frequent alternative
alleles are colored in green
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significantly negative FIS (FIS \ mean ? 3 SD., Supple-
mentary Fig. 2) compared with the rest of chromosome 13.
Of course, the excess of heterozygotes for the long hap-
lotype is to be expected, as most homozygotes at these loci
are likely to be prenatally lethal. Natural selection in the AJ
population could also result in the observed pattern of
haplotype structure. To investigate this possibility, we first
looked at the population differentiation (as measured by
FST) between AJ and CNJ individuals. The region sur-
rounding BRCA2 shows a pronounced level of differenti-
ation compared with the remainder of chromosome 13
(Fig. 3a) and compared to the rest of the genome (data not
shown). Although extreme FST values (compared to a
genome-wide distribution) have been used to detect natural
selection (Akey et al. 2002), our observation is most likely
caused by an inherent bias in the ascertainment of our
samples. The individuals in the cohort used in this analysis
were specifically chosen because they had a mutation in
their BRCA2 gene. The mutation spectrum observed in AJ
women is inherently different from that observed in CNJ
and therefore the increased FST is due to skewed ascer-
tainment rather than true population differentiation. We
observe the same effect on chromosome 17 in a cohort of
women harboring BRCA1 mutations (Fig. 3b). However, if
we look at FST among an independent cohort of randomly
ascertained Ashkenazi individuals and the HapMap CEU
(Olshen et al. 2008), we observe no increase in values in
the BRCA1 or the BRCA2 region, nor do we see an increase
in the BRCA1 region in the BRCA2 cohort (data not
shown).
A skew in the allele frequency spectrum (quantified with
Tajima’s D statistic) can also be used to find regions under
natural selection. Both demographic and selection events
can result in non-zero D values, but demographic effects
should be observed across the whole genome. We used the
method implemented by Carlson et al. (Carlson et al. 2005)
to calculate D values in 100-kb sliding windows. By
comparing the value of Tajima’s D in windows across the
BRCA2 region with the distribution across the entire gen-
ome, we can determine whether this region is truly
exceptional. Tajima’s D values across the entire genome
range from -1.82 to 6.58 with a mean value of 3.07
(Fig. 4). Of the 201 windows across the region of interest,
0 fall below the 5th percentile (D = 1.081) and 3 fall
above the 95th percentile (D = 4.786) of the genome-wide
distribution suggesting that this region is not an outlier.
The skew of the genome-wide distribution toward positive
values is consistent with a recent population bottleneck.
This is an empirical confirmation of the simulations—the
past demography of the Ashkenazi has resulted in many
genomic regions with a recent coalescence and unusual
differentiation from the CNJ population (Olshen et al.
2008; Ostrer 2001).
Discussion
A number of genetic diseases are more frequent in Ash-
kenazi Jews than in other populations. In 1978, two classic
papers independently explored the elevated frequency of
a
b
Fig. 3 Population differentiation among Ashkenazi and CNJ women.
a FST between 372 Ashkenazi and 1,441 Caucasian, non-Jewish
women across chromosome 13. b FST between 613 Ashkenazi
(carriers of the 185delAG and 5382insC founder mutations) and 2,186
Caucasian, non-Jewish (carriers of non-founder mutations) women
across chromosome 17. The peaks of FST occur in the region
surrounding BRCA2 and BRCA1 in (a) and (b), respectively,
represented by the black boxes
Fig. 4 Genome-wide distribution of Tajima’s D in 372 AJ women.
D statistics were estimated for 100-kb sliding windows
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Tay Sach’s disease in the AJ population using the same
statistical analysis, but came to two different conclusions:
One group argued that genetic drift is unlikely to have
produced the observed gene frequency (Chakravarti and
Chakraborty 1978); while the other group suggested that
historical bottlenecks and genetic drift could explain the
frequency (Wagener et al. 1978). In an accompanying
editorial, Ewens (Ewens 1978) concluded that ascertain-
ment bias and different assumptions about effective pop-
ulation size of the AJ affected the calculations. While we
did not specifically assign the effective population size, our
simulation parameters are based on the best inference of
historical Ashkenazi population demography [Slatkin
(2004)]. In addition, we explored the impact of ascertain-
ment bias on our conclusions by examining FST deviations
in the unbiased Olshen et al. sample of AJ in the BRCA1
and BRCA2 regions, and found no significant increase in
FST. We also examined the BRCA2 mutation carriers in the
instant study for significant FST deviation in the BRCA1
region and found none. Finally, our previous work (Olshen
et al. 2008) searched for evidence of long haplotypes
throughout the genomes of randomly ascertained AJ and
the HapMap CEU and found a similar pattern: extended
haplotypes were absent, or present to a much lesser extent,
in the CEU just like the CNJ in the present study.
BRCA1 and BRCA2 founder mutations are observed at a
higher frequency in Ashkenazi Jews compared to mutations
in other populations. We found long-range haplotype
structure in a high percentage of AJ chromosomes carrying
one of the three BRCA1 or BRCA2 founder mutations. We
considered three competing hypotheses for the origin of
this extended haplotype. The first, which we quickly
excluded, was endogamy and/or positive assortative mat-
ing. If there were positive assortative mating for traits
conferred by this genomic region, this would inflate the
homozygosity, reduce the effect of recombination and
potentially give rise to an extended haplotype. This
hypothesis was rejected because none of the predictions
regarding departures from Hardy–Weinberg frequencies
were met.
The second hypothesis was that positive natural selec-
tion could have driven up the frequency of a specific
haplotype. The fact that simulations under a neutral model
with random drift (and a founder effect) can generate
haplotype blocks of this size does not prove that natural
selection did not occur. However, we do know that the
demography of the Ashkenazi was different from CNJs,
and that other regions of the genome also show elevated
FST. It would seem that invoking natural selection for every
region of the genome that appears differentiated is not the
most parsimonious solution.
The third hypothesis was that there was a local bot-
tleneck effect from a population size constriction, and this
resulted, by chance in this demographic scenario, in a
a b
Fig. 5 Haplotype network results from analyzing the eight SNPs that
make up the core BRCA2 haplotype. Diagrams constructed using
haplotypes observed at a frequency of at least 1% are labeled. The
dark gray sphere (H1) represents the core haplotype. a Network for
AJ chromosomes. b Network for CNJ chromosomes. Frequency of
each haplotype can be found in Supplementary Table 1. The size of
each sphere is proportional to its frequency in the sample
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large haplotype block at high frequency in the BRCA2
region. This would agree with the global analysis by
Atzmon, et al. (Atzmon et al. 2010), who showed that
IBD sharing of chromosomal segments across the entire
genome in AJ individuals was consistent with a severe
population bottleneck followed by expansion. This
explanation was also consistent with several objective
attributes of our data: (1) Local reductions in variation are
expected when a population goes through a bottleneck
(Haddrill et al. 2005) and the BRCA2 region is not at all
exceptional with respect to the distortion in its site fre-
quency spectrum, as measured by Tajima’s D. (2) The
haplotype network diagrams of both the Ashkenazi and
CNJ demonstrated that the 6174delT mutation arose on
the major Caucasian haplotype (Fig. 5). This is consistent
with previous reports of very recent ascendancy of the
deleterious mutation to high frequency in the AJ (Neu-
hausen et al. 1998).
One of the more compelling arguments against the
hypothesis that genetic drift and founder effects explain all
the AJ and CNJ genetic differences is that it is unlikely for
common genetic diseases to cluster in so few pathways if
drift were the only force acting on allele frequencies. But in
the absence of a mechanism by which BRCA1 and BRCA2
variants might have been selectively favored in the Ash-
kenazi, the most satisfactory explanation of the unusual
haplotype pattern in this region remains random genetic
drift and a founder effect. The hypothesis that disabling
homologous recombination positively influences cortical
differentiation (Cochran et al. 2006) is without foundation,
and a recent report that BRCA2 mutation in AJ is a con-
sequence of selection, on the basis of iHS tool application
(Bray et al. 2010) is, in our view, a misinterpretation. The
observation that other recent populations (e.g., BRCA2
999del5 mutation in Icelanders) manifest different founder
mutations (Thorlacius et al. 1997) is consistent with our
simulations and, while the above hypotheses are not
mutually exclusive, a population bottleneck remains the
most parsimonious explanation for the observed haplotype
pattern.
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Appendix A—msHOT command
/mshot 412 1 -r 1.0 2087508 -s 545 -v 30 46440 55764
92.72 94074 101467 172.87 116262 120708 84.46 158286
166715 60.34 188386 195853 69.08 203508 207586 27.50
408508 419950 23.61 425890 436582 14.86 531508
540447 22.26 661931 673793 120.99 770385 780441
29.47 815508 819627 29.47 824410 832053 71.03 896479
899758 92.66 907490 914508 66.72 927238 930508 5.91
951526 958508 33.76 967928 979794 50.26 996275
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999508 107.56 1084508 1088508 28.62 1091504 1098508
126.14 1616508 1619571 340.72 1621508 1627508 15.09
1660329 1663531 623.28 1675309 1679508 35.42
1686508 1706508 5.02 1850331 1854508 65.25 1883508
1887508 237.76 1962482 1967508 38.82 2055476
2087508 53.91 -G 2355557.4 -eG 0.0000018 0.0000571
-eN 0.0000018 0.095.
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